{{위키데이터 속성 추적}}
{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458780973
| image = Atovaquone Structural Formula V.1.svg
| width = 215
| image2 = Atovaquone-from-xtal-Mercury-3D-bs.png

<!--Clinical data-->
| tradename = 메프론(Mepron)
| Drugs.com = {{drugs.com|monograph|atovaquone}}
| MedlinePlus = a693003
| pregnancy_US = C
| pregnancy_category =
| legal_US = Rx-only
| legal_UK = POM
| legal_UK_comment =<ref>{{웹 인용| title=Wellvone 750mg/5ml oral suspension - Summary of Product Characteristics (SmPC) | website=(emc) | date=28 November 2019 | url=https://www.medicines.org.uk/emc/product/952/smpc | access-date=18 September 2020}}</ref>
| routes_of_administration = [[경구 투여]]
| ATC_prefix = P01
| ATC_suffix = AX06
| ATC_supplemental =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life = 2.2~3.2일

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 95233-18-4
| PubChem = 74989
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01117
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10482034
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Y883P1Z2LT
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00236
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 575568
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1450

<!--Chemical data-->
| IUPAC_name = ''trans''-2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione
| C=22 | H=19 | Cl=1 | O=3
| smiles = OC=2C(=O)c1ccccc1C(=O)C=2[C@@H]3CC[C@H](CC3)c4ccc(Cl)cc4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KUCQYCKVKVOKAY-CTYIDZIISA-N
| melting_point = 216
| melting_high = 219
}}

'''아토바쿠온'''(Atovaquone)은 '''메프론'''(Mepron)이라는 상품명으로 판매되는 약물로, [[주폐포자충 폐렴]](PCP)의 치료와 예방에 사용되는 항미생물제이다.<ref>{{웹 인용| title=Atovaquone Oral SUSPENSION- atovaquone suspension | website=DailyMed | date=10 December 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b31ff20a-c363-4be0-9bc0-3081c163b63c | access-date=18 September 2020}}</ref> 또한 [[아토바쿠온/프로구아닐]]은 [[말라리아]] 치료 및 예방에 이용된다.

[[나프토퀴논]]에 속하는 화학 물질로, 구조식은 하이드록시-1,4-나프토퀴논이다. 구조상 [[유비퀴논]]과 [[라우손 화합물|라우손]]의 [[유사체]]이다.

== 의학적 사용 ==
아토바쿠온을 치료 및 예방에 이용하는 질환은 다음과 같다.
* 경증 [[주폐포자충 폐렴]](PCP).<ref name="pmid8479489">{{저널 인용| vauthors = Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, Clumeck N, Masur H, Lancaster D, Chan C | display-authors = 6 | title = Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS | journal = The New England Journal of Medicine | volume = 328 | issue = 21 | pages = 1521–1527 | date = May 1993 | pmid = 8479489 | doi = 10.1056/NEJM199305273282103 | doi-access = free }}</ref><ref name="pmid7880228">{{저널 인용| vauthors = Dohn MN, Weinberg WG, Torres RA, Follansbee SE, Caldwell PT, Scott JD, Gathe JC, Haghighat DP, Sampson JH, Spotkov J, Deresinski SC, Meyer RD, Lancaster DJ | display-authors = 6 | title = Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group | journal = Annals of Internal Medicine | volume = 121 | issue = 3 | pages = 174–180 | date = August 1994 | pmid = 7880228 | doi = 10.7326/0003-4819-121-3-199408010-00003 | s2cid = 24263604 }}</ref> 중증인 경우에는 사용하지 않으며, 대개 1차 치료제는 [[트리메토프림/설파메톡사졸]](TMP-SMX, 박트림)이다. [[설폰아마이드 알레르기]]가 있거나 TMP-SMX에 내약성이 좋지 못한 환자에게 아토바쿠온을 대신 투여하는 것을 고려할 수 있다.
* [[톡소포자충증]]<ref name="pmid12461021">{{저널 인용| vauthors = Djurković-Djaković O, Milenković V, Nikolić A, Bobić B, Grujić J | title = Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii | journal = The Journal of Antimicrobial Chemotherapy | volume = 50 | issue = 6 | pages = 981–987 | date = December 2002 | pmid = 12461021 | doi = 10.1093/jac/dkf251 | doi-access = free }}</ref>
* [[말라리아]]. 아토바쿠온과 [[프로구아닐]]은 [[말라론]]의 구성 성분이다. 아토바쿠온/프로구아닐은 또 다른 [[항말라리아제]]인 [[메플로퀸]]보다 부작용은 적지만 비용이 비싸다.<ref>[http://healthlink.mcw.edu/article/979237802.html  Malarone: New Malaria Medication With Fewer Side-effects] {{webarchive |url=https://web.archive.org/web/20060514041931/http://healthlink.mcw.edu/article/979237802.html |date=May 14, 2006 }}</ref> 내성이 보고된 사례가 있다.<ref name="pmid12649236">{{저널 인용| vauthors = Färnert A, Lindberg J, Gil P, Swedberg G, Berqvist Y, Thapar MM, Lindegårdh N, Berezcky S, Björkman A | display-authors = 6 | title = Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports | journal = BMJ | volume = 326 | issue = 7390 | pages = 628–629 | date = March 2003 | pmid = 12649236 | pmc = 151974 | doi = 10.1136/bmj.326.7390.628 }}</ref>
* [[바베시아열원충증]]에서 [[경구 투여|경구]] [[아지트로마이신]]과 병용하기도 한다.<ref>{{저널 인용| vauthors = Krause PJ, Lepore T, Sikand VK, Gadbaw J, Burke G, Telford SR, Brassard P, Pearl D, Azlanzadeh J, Christianson D, McGrath D, Spielman A | display-authors = 6 | title = Atovaquone and azithromycin for the treatment of babesiosis | journal = The New England Journal of Medicine | volume = 343 | issue = 20 | pages = 1454–1458 | date = November 2000 | pmid = 11078770 | doi = 10.1056/NEJM200011163432004 | doi-access = free }}</ref>

한편 가축으로 기르는 소의 바베시아열원충증에 쓰기도 하는데, 특히 [[이미도카브]] 내성이 우려될 때 유용하다.<ref name="Vial-Gorenflot-2006">{{저널 인용| vauthors = Vial HJ, Gorenflot A | title = Chemotherapy against babesiosis | journal = Veterinary Parasitology | volume = 138 | issue = 1–2 | pages = 147–160 | date = May 2006 | pmid = 16504402 | doi = 10.1016/j.vetpar.2006.01.048 }}</ref>


== 각주 ==
{{각주}}

== 외부 링크 ==
* {{위키공용분류-줄}}
* {{웹 인용| url = https://druginfo.nlm.nih.gov/drugportal/name/atovaquone | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Atovaquone }}
* {{저널 인용| vauthors = Kessl JJ, Hill P, Lange BB, Meshnick SR, Meunier B, Trumpower BL | title = Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae | journal = The Journal of Biological Chemistry | volume = 279 | issue = 4 | pages = 2817–2824 | date = January 2004 | pmid = 14576156 | doi = 10.1074/jbc.M309984200 | doi-access = free }}

{{전거 통제}}
[[분류:항말라리아제]]
[[분류:항원충제]]
[[분류:1,4-나프토퀴논]]
[[분류:하이드록시나프토퀴논]]
[[분류:클로로아렌]]
[[분류:글락소스미스클라인의 제품]]